Abdelaal Hazem F M, Chan Edward D, Young Lisa, Baldwin Susan L, Coler Rhea N
Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98145, USA.
Department of Academic Affairs and Medicine, National Jewish Health, Denver, CO 80206, USA.
Microorganisms. 2022 Jul 19;10(7):1454. doi: 10.3390/microorganisms10071454.
() is an opportunistic pathogen usually colonizing abnormal lung airways and is often seen in patients with cystic fibrosis. Currently, there is no vaccine available for in clinical development. The treatment of -related pulmonary diseases is peculiar due to intrinsic resistance to several commonly used antibiotics. The development of either prophylactic or therapeutic interventions for pulmonary infections is hindered by the absence of an adequate experimental animal model. In this review, we outline the critical elements related to virulence mechanisms, host-pathogen interactions, and treatment challenges associated with pulmonary infections. The challenges of effectively combating this pathogen include developing appropriate preclinical animal models of infection, developing proper diagnostics, and designing novel strategies for treating drug-resistant .
（）是一种机会性病原菌，通常定植于异常的肺气道，常见于囊性纤维化患者。目前，尚无用于临床开发的针对（）的疫苗。由于对几种常用抗生素具有内在抗性，与（）相关的肺部疾病的治疗较为特殊。缺乏合适的实验动物模型阻碍了针对（）肺部感染的预防性或治疗性干预措施的开发。在本综述中，我们概述了与（）毒力机制、宿主-病原体相互作用以及与（）肺部感染相关的治疗挑战有关的关键要素。有效对抗这种病原体面临的挑战包括开发合适的临床前感染动物模型、开发适当的诊断方法以及设计治疗耐药（）的新策略。
